Ginkgo biloba Special Extract in Dementia with Neuropsychiatric Features

Napryeyenko, Oleksandr; Borzenko, Irina

doi:10.1055/s-0031-1296579

Cited by 60 publications

(64 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 of 57 studies were not considered from the Cochrane review 3 due to the following reasons: (Schubert and Halama, 1993) assessed acute doses, other problems were the lack of appropriate statistical reports (Arrigo, 1986;Arrigo and Cattaneo, 1985;Mancini et al, 1993;Maurer et al, 1997) and lack of domain-specific objective tests (Augustin, 1976;Brüchert et al, 1991;Chartres et al, 1987;Eckmann, 1990;Eckmann and Schlag, 1982;Haase et al, 1996;Halama et al, 1988;Kade and Miller, 1993;Kanowski et al, 1996;Le Bars et al, 1997;Mazza et al, 2006;Napryeyenko and Borzenko, 2007;Pidoux et al, 1983;Schmidt et al, 1991;Schneider et al, 2005;Taillandier et al, 1986). Four other studies were not considered as they only provided physiological data (Költringer et al, 1995;Schulz et al, 1991;Schultz, 2002;Semlitsch et al, 1995).…”

Section: Selection Of Relevant Studiesmentioning

confidence: 99%

Ginkgo biloba: specificity of neuropsychological improvement—a selective review in search of differential effects

Kaschel

2009

Human Psychopharmacology

View full text Add to dashboard Cite

Extracts of Ginkgo biloba are widely used for the treatment of cognitive impairment. Whereas reviews have focused on the question whether ginkgo is effective to enhance cognition in general, little is known about specificity of improvement. This might be crucial for future trials, thus enabling hypotheses about sensitive outcome measures. Therefore, this article summarizes such information, i.e. neuropsychological effects of chronic administration of ginkgo in healthy and cognitively impaired subjects of any age. Objective psychometric test results were considered if they reflected distinct cognitive functions from randomized controlled group-studies (RCT). We reviewed 29 RCTs yielding 209 placebo-drug comparisons of psychometric scores in four different cognitive domains comprising 14 sub-functions. Whereas little specific information can be obtained from trials for treatment of dementia, a pattern of pharmacological actions on cognitive processes emerges here from studies for mild cognitive impairment (MCI), depression, multiple sclerosis and healthy young and elderly subjects. There is consistent evidence that chronic administration improves selective attention, some executive processes and long-term memory for verbal and non-verbal material. Further trials should be more comprehensive as there are few data available on some cognitive functions and psychometric flaws in the selection of tests and the interpretation of their results favouring predominantly beta-errors. Thus, though this pattern is encouraging it also asks for a cautious interpretation to date.

show abstract

Section: Selection Of Relevant Studiesmentioning

confidence: 99%

Ginkgo biloba: specificity of neuropsychological improvement—a selective review in search of differential effects

Kaschel

2009

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The Ginkgo biloba extract EGb 761® has been tested in a series of randomized, placebo-controlled trials and found effective in the treatment of dementia syndromes, namely Alzheimer's disease (AD), vascular dementia (VaD) and mixed forms of both [1][2][3][4][5][6][7]. Findings from one trial in AD which employed particularly restrictive eligibility criteria with respect to neuropsychiatric symptoms and vascular pathology suggested that EGb 761® may be more effective in patients with at least mild neuropsychiatric symptoms than in those who do not have such symptoms at all [8].…”

Section: Introductionmentioning

confidence: 99%

Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial

Ihl

Tribanek

Bachinskaya

2010

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…Findings from various studies have shown that there is evidence for an association between late-life depression and dementia, especially Alzheimer’s disease (AD) [30-32]. Still it is not clear whether a depression history is a risk factor for AD or whether neuropathologic changes in AD may result in a depression.…”

Section: Discussionmentioning

confidence: 99%

Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany

Czeche¹,

Schüssel²,

Franzmann³

et al. 2013

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundGinkgo biloba drugs (Gb) are reimbursed within the German statutory health insurance (SHI) scheme for treatment of dementia. In 2008, a novel Gb product containing 240 mg Ginkgo extract EGb761® per tablet was introduced aiming to facilitate medication use by incorporating the recommended daily dose in one single tablet. The aim of this study was to evaluate the relationship between dosage strength and persistence in a representative population of patients treated with Gb.MethodsRetrospective cohort study in ambulatory drug claims database within the German SHI system. Persistence was defined as continuous treatment with an allowable gap of 20% between refills. Multivariate regression models were conducted to identify variables associated with persistence.ResultsAmong 13,810 patients initiating treatment with Gb in 2008, 430 (3.1%) received a dosage strength of 240 mg, 7,070 (51.2%) a dosage strength of 120 mg and 6,310 (45.7%) dosage strengths containing less than 120 mg Gb per tablet. After 6 months, persistence was highest for patients treated with the 240 mg dosage form (22.8% of patients), although persistence was low in general (5.7% and 0% of patients treated with 120 mg and less than 120 mg, respectively). Risk for non-persistence was reduced in patients receiving 240 mg products compared to 120 mg (HR = 0.63; 95%CI 0.57 – 0.70).ConclusionsPatients initially treated with Gb 240 mg were more persistent compared to those receiving lower dosage strengths. Nevertheless, persistence with Gb therapy is generally low and should be improved in order to better realize therapeutic effects.

show abstract

Ginkgo biloba Special Extract in Dementia with Neuropsychiatric Features

Abstract: The data add further evidence on the safety and efficacy of EGb 761 in the treatment of cognitive and non-cognitive symptoms of dementia.

Cited by 60 publications

References 21 publications

Ginkgo biloba: specificity of neuropsychological improvement—a selective review in search of differential effects

Ginkgo biloba: specificity of neuropsychological improvement—a selective review in search of differential effects

Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial

Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany

Contact Info

Product

Resources

About